DARTS vs CETSA vs TPP: Choosing a Label-Free Target-Engagement and Target-Deconvolution Strategy

Label-free target deconvolution is attractive precisely when a compound cannot or should not be converted into an affinity probe. DARTS, CETSA, and TPP all use compound-associated changes in protein state, but they capture different phenotypes: protease protection, focused thermal solubility, or proteome-wide thermal behavior.

That difference matters when a project has to decide whether it needs to nominate candidates, test engagement of a suspected target, or build a discovery-scale shortlist after a phenotypic result. DARTS, CETSA, and TPP can each be valuable in those settings, but none on its own converts a stability phenotype into a verified direct-target claim.

Key Takeaways: DARTS vs CETSA vs TPP

• DARTS, CETSA, and TPP are label-free stability-based strategies, but each observes a different perturbation and scale of evidence.
• DARTS asks whether compound-associated protection changes susceptibility to proteolysis; CETSA examines apparent thermal stability of a nominated target; TPP expands thermal profiling to a proteome-scale dataset.
• For a known target in a relevant biological context, CETSA may be the most direct focused readout. For unknown targets, TPP is generally better aligned with discovery.
• No method alone proves a direct target; high-confidence deconvolution requires orthogonal binding, competition, functional, or genetic evidence.

DARTS vs CETSA vs TPP: Key Differences

Choose DARTS when protease-protection behavior is the informative perturbation, CETSA when a nominated target needs a focused thermal-engagement readout, and TPP when the project must prioritize target candidates across the proteome. All three are label-free approaches that infer compound-associated protein-state changes, but they differ in what is perturbed, what is measured, and how broadly the evidence can be interpreted.

Drug affinity responsive target stability (DARTS) examines whether a protein becomes relatively protected from proteolysis in the presence of a compound. CETSA measures how a protein’s soluble fraction changes after a controlled heat challenge. Thermal proteome profiling (TPP) extends the thermal-stability concept to mass-spectrometric, proteome-scale measurement. Each can generate valuable candidates; none should be described as a stand-alone direct-binding proof.

When to Use DARTS for Target Identification

DARTS is attractive when a compound-associated conformational change may alter a protein’s susceptibility to proteolysis. It can be used in discovery-oriented workflows without attaching a chemical probe to the compound. The output is a protection phenotype, which can help nominate candidates for later confirmation.

The strength of DARTS is also its interpretive boundary. Protection is influenced by protein state, complex context, protease accessibility, and matrix behavior. A protected band or MS feature should be treated as a candidate observation to prioritize rather than a final assignment of direct molecular binding. DARTS is most useful when it is integrated with a second line of evidence that tests the nominated target more directly.

When to Use CETSA for Target Engagement

CETSA is suited to a known or strongly suspected target when the question is whether compound treatment is associated with a measurable thermal-stability phenotype in a biologically relevant sample context. It is more focused than TPP and can be used to compare condition-dependent engagement of a nominated protein.

The value of CETSA comes from biological context, not from an assumption that every thermal shift is direct binding. Complex assembly, protein modification, and pathway effects can change stability. For this reason, a focused CETSA result is most defensible when interpreted with target abundance, compound controls, and an orthogonal interaction assay. The foundational CETSA study established the use of thermal stabilization to evaluate target interactions in cells (Jafari et al., 2014).

If the project question is “does this nominated protein show a compound-associated thermal phenotype under these conditions?”, choose CETSA. If the question is “which proteins might explain the phenotype?”, move to a proteome-scale TPP design.

When to Use TPP for Target Deconvolution

TPP is appropriate when the starting point is an unknown target landscape, a phenotypic compound response, or a need to compare stability behavior across many proteins. It can expose candidate on-target and pathway-associated changes in one integrated dataset. This breadth makes it valuable for target deconvolution, but it also raises the standard for prioritization: candidates must be ranked by reproducibility, response quality, biological plausibility, and the potential for indirect effects.

The analysis should distinguish “proteins with altered stability” from “verified direct targets.” The first is the direct output of TPP; the second requires confirmatory work. Thermal proteome profiling services are therefore most useful when the discovery brief states how an initial candidate list will be narrowed through orthogonal evidence.

DARTS, CETSA, and TPP differ in perturbation, readout, and discovery scope.

Target Engagement vs Target Deconvolution

Target engagement asks whether a molecule is associated with a relevant target state in the study context. Target deconvolution asks which molecular interaction or target set explains an observed biological effect. These questions overlap but are not interchangeable. CETSA can strengthen engagement evidence for a nominated protein; TPP can generate a broader candidate list; DARTS can provide an alternative stability-based nomination route.

The project should name the claim before selecting the method. A proposal that requires a single known target’s engagement should not automatically be expanded into a broad discovery study. Conversely, a phenotypic project with many plausible targets should not be forced into a single-protein assay too early. Target-identification and validation analysis can combine discovery-scale prioritization with direct-interaction follow-up.

How to Choose DARTS, CETSA, or TPP

If you need a focused thermal answer for a known protein, choose CETSA. If you need a proteome-wide path to target candidates, choose TPP. If protease protection is the relevant discovery signal, choose DARTS. In all cases, reserve direct-target conclusions for an evidence package that includes a method suited to molecular interaction.

Validation After DARTS, CETSA, or TPP

Orthogonal Validation After DARTS, CETSA, or TPP

The appropriate second method depends on the unresolved claim. SPR and BLI can address kinetic interaction behavior for suitable purified systems. MST can test solution-phase binding, while ITC adds thermodynamic and stoichiometric information. Structural or dynamic questions may require HDX-MS, NMR, or cross-linking approaches.

An orthogonal result should not be chosen merely to “confirm” the first assay. It should remove a known ambiguity. A DARTS or CETSA candidate may need direct-affinity evidence; a TPP target list may need a strategy to distinguish a direct binder from a downstream responder; a kinetic interaction may still need a functional readout to show biological relevance.

A stability phenotype becomes more informative when paired with the right orthogonal evidence.

Common DARTS, CETSA, and TPP Errors

• Calling any stability change a direct target without considering complex-mediated or pathway-mediated effects.
• Using a focused assay when the biological question actually requires unbiased target prioritization.
• Treating a proteome-wide candidate list as a final mechanism without an explicit validation plan.
• Comparing DARTS, CETSA, and TPP solely by throughput instead of by the target claim and biological context.
• Ignoring protein state, matrix differences, and replicate structure when comparing stability phenotypes.

A useful study design makes the next decision visible before samples are committed: candidate nomination, engagement comparison, target ranking, or direct interaction validation. This avoids producing a stability dataset that cannot be translated into a defensible research conclusion.

Choosing the Right Matrix for Label-Free Target Engagement

The matrix determines what a stability phenotype can mean. A lysate may simplify access to proteins and reduce cellular permeability as a confounder, but it does not preserve every aspect of living-cell localization, metabolism, and complex state. Intact-cell CETSA or TPP can retain more native context, while tissue-derived material may be indispensable when the scientific hypothesis depends on a specific biological source.

The project brief should state which context must be preserved for the conclusion to be useful. If the claim concerns a compound-associated protein state in intact cells, a focused CETSA design may be appropriate. If the research question is discovery within a complex target landscape, TPP can provide broader context. If a protease-protection approach fits the available material and hypothesis, DARTS can serve as a candidate-nomination route.

None of these choices are hierarchy labels. They are trade-offs between biological context, discovery breadth, and the physical perturbation that the protein state is expected to reveal. Selecting the matrix and method together makes the eventual claim easier to defend.

Label-Free Target Deconvolution Study Design

How to Prioritize TPP and DARTS Candidates

A broad candidate list is useful only if it can be narrowed transparently. For TPP, that means considering response reproducibility, the coherence of the thermal pattern, known biology, expression in the relevant model, and whether a candidate could plausibly be an indirect responder. For DARTS, it means asking whether the protection phenotype can be reproduced and whether another method can test direct interaction.

The validation method should be assigned while candidates are still being prioritized. A soluble purified target may be appropriate for MST, SPR, BLI, or ITC. A candidate whose mechanism is likely conformational may warrant HDX-MS or NMR. A protein that changes in a broad TPP experiment but cannot be isolated in a relevant state may need a different functional or genetic evidence branch.

If the project needs a ranked hypothesis list, choose the broadest method whose output can be validated. If it needs focused engagement evidence for one known protein, choose CETSA. This decision-ready approach prevents a label-free screen from ending as an unactionable list.

How to Report Label-Free Target Findings

A label-free report should specify which proteins were measured as stability phenotypes, how candidates were prioritized, and why each proposed validation method fits the candidate. The report should not collapse that sequence into a list of “targets” unless direct interaction evidence has been independently established.

For a DARTS observation, the follow-up may focus on whether the protein shows a reproducible protection phenotype and whether an independent interaction readout is feasible. For CETSA, it may focus on the relation between focused thermal engagement and the biological model. For TPP, it should articulate why particular proteins or complexes have priority over broader downstream effects.

This structure creates a useful bridge from discovery to action. It lets a team decide whether to validate a candidate with solution affinity, kinetics, structural mapping, or a relevant functional perturbation instead of spending resources equally on every stability change.

Label-Free Target Deconvolution Study Planning

The most useful label-free strategy is the one that produces candidates the project can realistically validate. A focused CETSA result should lead to a direct-interaction or functional question. A DARTS nomination should lead to independent confirmation of the protected candidate. A broad TPP result should lead to a transparent candidate-ranking and validation plan. Thinking about that second step before the first sample is analyzed turns a stability phenotype into an actionable research path rather than an isolated assay result.

Planning a DARTS, CETSA, or TPP Study

Before execution, nominate an orthogonal route for the candidates that matter most. A validation-ready plan is the best safeguard against turning a stability phenotype into an unsupported target claim.

FAQ

Can DARTS identify direct protein targets?

DARTS can nominate proteins with compound-associated protease-protection behavior. Direct-target confirmation requires orthogonal interaction or functional evidence.

Is CETSA better than TPP for a known target?

For a focused question about a nominated target’s thermal engagement, CETSA may be the more direct study. TPP is preferable when broader proteome-level context or candidate discovery is required.

Can TPP distinguish direct targets from indirect effects?

TPP identifies altered thermal-stability phenotypes across proteins. Interpretation must combine response quality, biology, and orthogonal validation to distinguish direct binders from indirect responders.

Can CETSA and TPP be used in the same project?

Yes. A broad TPP study can prioritize candidates, while focused CETSA or ITDR work can examine selected proteins in greater depth. The sequence should be driven by the target hypothesis.

Is DARTS suitable when the target is unknown?

DARTS can support candidate nomination through compound-associated protease protection. It should be paired with an independent validation plan before a direct-target conclusion is made.

What makes a TPP candidate high priority?

Priority should reflect reproducibility, response behavior, biological relevance, and feasibility of an orthogonal test. The largest stability change alone is not sufficient.

Does label-free mean no controls are needed?

No. Label-free refers to the absence of a covalent probe or target tag in the core measurement. Biological, vehicle, and interpretation controls remain essential to distinguish compound-associated behavior from unrelated variation.

Plan a Target-Deconvolution Study

A concise project discussion can map the compound class, sample context, hypothesis, and intended conclusion to an appropriate label-free strategy and an orthogonal validation branch. The goal is not to maximize the number of assay formats, but to build an evidence chain that supports the scientific decision.